BPC
BIS icon

Banque Pictet & Cie’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Banque Pictet & Cie’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-850
Closed -$215K – 323
2016
Q3 		$215K Buy
+850
New +$226K 0.01% 312

Other funds holding BIS

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Banque Pictet & Cie's BIS Position: Q4 2016 in Review

Banque Pictet & Cie sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q4 2016, closing a stake of 850 shares — an estimated $215K sold.

Banque Pictet & Cie first reported a position in BIS in Q3 2016 and held it in 1 quarter. The position peaked at $215K in Q3 2016. 13 funds tracked by Wall St. Rank hold BIS as of Q4 2016.

  • Banque Pictet & Cie reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q4 2016 after selling out during the quarter.
  • Banque Pictet & Cie sold 850 ProShares UltraShort NASDAQ Biotechnology shares in Q4 2016, an estimated $215K.
  • Banque Pictet & Cie first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2016 and held it in 1 quarter.
  • Banque Pictet & Cie's ProShares UltraShort NASDAQ Biotechnology position peaked at $215K in Q3 2016.
  • 13 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q4 2016.

Based on Banque Pictet & Cie's 13F filing for Q4 2016, filed 6 Feb 2017.